Drug Interaction Report

MONITOR: Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inducers may decrease the systemic exposure (AUC) of avatrombopag which may lead to reduced efficacy.

MANAGEMENT: No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.

ADJUST DOSING INTERVAL: Food reduces the variability in oral absorption and bioavailability of avatrombopag. According to the product labeling, avatrombopag peak plasma concentration (Cmax) and systemic exposure (AUC) were not affected when administered with either a low-fat (500 calories; 3 g fat, 15 g proteins, 108 g carbohydrates) or high-fat (918 calories; 59 g fat, 39 g proteins, 59 g carbohydrates) meal. However, the variability of avatrombopag exposure was reduced by 40% to 60% with food, and the time to reach Cmax was delayed by 0 to 2 hours relative to the fasted state.

MANAGEMENT: To ensure consistent absorption and plasma drug levels, avatrombopag should be taken with food.